PerpEquities

Innovent Biologics, Inc. (INNOVENT) 재무상태표

HKSE · Healthcare · Biotechnology · 직원 8,754명 · CEO De-Chao Yu

주가
HK$80.65 +1.13%
시가총액
HK$1410억
기업가치
CN¥1040억
최근 실적
Q2 '26 2026-06-30 제출
다음 실적
2027-03-31

Innovent Biologics, Inc. (INNOVENT)의 Q2 '26말 현금 및 단기투자는 CN¥200억, 리스 포함 차입금은 CN¥23.2억입니다. 자산총계 CN¥416억, 부채총계 CN¥209억, 주주지분 CN¥207억.

재무상태표

재무상태표추세Q4 '20Q2 '21Q4 '21Q2 '22Q4 '22Q2 '23Q4 '23Q2 '24Q4 '24Q2 '25Q4 '25Q2 '26
자산
현금 및 현금성자산CN¥12.8억CN¥44.6억CN¥13.6억CN¥13.5억CN¥10.2억CN¥13.3억CN¥101억CN¥81.7억CN¥75.1억CN¥95.4억CN¥174억CN¥174억
단기투자CN¥67.7억CN¥62.2억CN¥65.8억CN¥56.8억CN¥72.5억CN¥63.2억CN¥8.68억CN¥4.63억CN¥3.76억CN¥0CN¥8.87억CN¥26.2억
매출채권CN¥6.4억CN¥11.7억CN¥11.8억CN¥14억CN¥9.12억CN¥15.6억CN¥10.1억CN¥13.7억CN¥15.7억CN¥17.2억CN¥17.5억CN¥19억
재고자산CN¥7.06억CN¥11억CN¥13.5억CN¥14.8억CN¥14.3억CN¥13억CN¥9.68억CN¥6.9억CN¥8.22억CN¥11.3억CN¥13억CN¥18.8억
기타 유동자산CN¥5.48억CN¥14.8억CN¥9.75억CN¥24.7억CN¥18.1억CN¥24.3억CN¥4.84억CN¥3.61억CN¥0CN¥7.02억CN¥7.29억CN¥12.1억
유동자산CN¥94.7억CN¥134억CN¥116억CN¥112억CN¥115억CN¥114억CN¥134억CN¥110억CN¥103억CN¥131억CN¥220억CN¥250억
유형자산(순액)CN¥21.8억CN¥27.2억CN¥33.8억CN¥36.1억CN¥40.6억CN¥44.5억CN¥46.6억CN¥54.2억CN¥56.5억CN¥56억CN¥54.4억CN¥53.3억
장기투자-CN¥67.6억-CN¥61.7억CN¥5.12억CN¥4.65억CN¥7.13억-CN¥56.8억CN¥7.94억CN¥23억CN¥39억CN¥31.3억CN¥78.9억CN¥88.9억
무형자산CN¥3260만CN¥9690만CN¥7.72억CN¥8.16억CN¥12억CN¥11.9억CN¥2780만CN¥9.87억CN¥12.8억CN¥13.9억CN¥15.3억CN¥14.7억
이연법인세자산CN¥0CN¥0CN¥43.6억CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥4.72억
기타 비유동자산CN¥69.1억CN¥63.8억-CN¥43.3억CN¥7820만CN¥1.1억CN¥65.5억CN¥17.2억CN¥5.37억CN¥4.99억CN¥3.79억CN¥4.71억CN¥4.61억
비유동자산CN¥23.7억CN¥30.2억CN¥46.9억CN¥49.6억CN¥60.8억CN¥65.1억CN¥72억CN¥92.5억CN¥113억CN¥105억CN¥153억CN¥166억
자산총계CN¥118억CN¥165억CN¥162억CN¥162억CN¥176억CN¥179억CN¥206억CN¥203억CN¥216억CN¥236억CN¥374억CN¥416억
부채
매입채무CN¥1.21억CN¥2.77억CN¥1.95억CN¥2.36억CN¥3.26억CN¥2.16억CN¥3.73억CN¥2.21억CN¥3.58억CN¥4.32억CN¥4.95억CN¥9.31억
미지급비용CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥20.7억CN¥0CN¥0CN¥0CN¥0
단기차입금CN¥2.55억CN¥3.7억CN¥3.65억CN¥8.58억CN¥8.88억CN¥4.5억CN¥12억CN¥9.35억CN¥4.05억CN¥11.1억CN¥8.01억CN¥5.4억
미지급세금CN¥569만CN¥35.6만CN¥9280만CN¥2360만CN¥6100만CN¥6770만CN¥1.94억CN¥0CN¥0CN¥0CN¥0CN¥0
이연수익CN¥0CN¥0-CN¥10.3억CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥23.1억CN¥20.5억
기타 유동부채CN¥7.7억CN¥9.62억CN¥17.1억CN¥19억CN¥16.4억CN¥14.7억CN¥20.2억CN¥8.3억CN¥23.2억CN¥34.7억CN¥47.7억CN¥52.1억
유동부채CN¥14.9억CN¥22.4억CN¥30.5억CN¥34.8억CN¥35억CN¥28.7억CN¥44.8억CN¥41.3억CN¥43.7억CN¥50.1억CN¥83.9억CN¥93.2억
장기차입금CN¥9.25억CN¥14.7억CN¥20.2억CN¥18.1억CN¥22.2억CN¥28.9억CN¥23.3억CN¥22.7억CN¥24.1억CN¥22.6억CN¥19.9억CN¥17.6억
리스부채(비유동)CN¥1020만CN¥313만CN¥8640만CN¥8420만CN¥9870만CN¥8670만CN¥7340만CN¥6630만CN¥476만CN¥161만CN¥2600만CN¥2060만
이연수익(비유동)CN¥6.34억CN¥8.38억CN¥7.53억CN¥11.9억CN¥8.83억CN¥10.3억CN¥9.6억CN¥9.91억CN¥12.2억CN¥12.3억CN¥61.5억CN¥91억
이연법인세부채-CN¥6.34억-CN¥8.38억CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0CN¥0
기타 비유동부채CN¥0CN¥0CN¥34.2만CN¥11.9억CN¥10.5억CN¥12.7억CN¥2.63억CN¥14억CN¥17억CN¥19억CN¥6.43억CN¥6.6억
비유동부채CN¥15.7억CN¥23.1억CN¥28.6억CN¥30.9억CN¥33.6억CN¥42.4억CN¥36.2억CN¥37.4억CN¥41.2억CN¥41.6억CN¥88.1억CN¥115억
부채총계CN¥30.6억CN¥45.5억CN¥59.1억CN¥65.7억CN¥68.6억CN¥71.1억CN¥81억CN¥78.7억CN¥84.8억CN¥91.7억CN¥172억CN¥209억
자본
보통주 및 주식발행초과금CN¥9.7만CN¥10만CN¥10.1만CN¥10.1만CN¥10.5만CN¥10.6만CN¥11.2만CN¥11.2만CN¥11.3만CN¥11.4만CN¥11.9만CN¥12만
이익잉여금-CN¥99.8억-CN¥112억-CN¥154억-CN¥158억-CN¥167억-CN¥149억-CN¥158억-CN¥162억-CN¥159억-CN¥151억-CN¥151억-CN¥138억
기타포괄손익누계액CN¥2.2억CN¥5.95억CN¥3.97억CN¥5.58억CN¥7.64억CN¥7.62억CN¥9.71억CN¥10.4억CN¥13억CN¥144억CN¥15.5억CN¥12억
주주지분CN¥87.8억CN¥119억CN¥103억CN¥95.9억CN¥107억CN¥108억CN¥125억CN¥124억CN¥131억CN¥144억CN¥194억CN¥207억
부채(차입)
총차입금(리스 포함)CN¥12.1억CN¥18.6억CN¥25억CN¥27.7억CN¥32.3억CN¥34.5억CN¥36.2억CN¥33.5억CN¥28.3억CN¥33.8억CN¥28.2억CN¥23.2억
순차입금(차입금 - 현금)-CN¥6960만-CN¥26.1억CN¥11.4억CN¥14.1억CN¥22.1억CN¥21.2억-CN¥64.3억-CN¥48.2억-CN¥46.8억-CN¥61.6억-CN¥145억-CN¥151억

기업의 제출 서류를 표준화한 데이터입니다. 지출과 비용은 제공처가 보고한 부호를 그대로 유지합니다. 기간에 마우스를 올리면 종료일이 표시됩니다. 금액 단위는 CNY.

현금, 투자, 차입금

분기말

다른 재무제표

출처

재무제표, 부문 매출, 지표, 추정치는 기업의 제출 서류를 표준화한 데이터입니다.

데이터 기준일 2026-11-02 · 금액은 보고 통화 CNY 기준, 주가와 시가총액은 HKD 기준.